Medeze Group Valuation
Is MEDEZE-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MEDEZE-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MEDEZE-R (THB10) is trading above our estimate of fair value (THB3.03)
Significantly Below Fair Value: MEDEZE-R is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MEDEZE-R?
Other financial metrics that can be useful for relative valuation.
What is MEDEZE-R's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿10.68b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 13.4x |
Enterprise Value/EBITDA | 29.8x |
PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does MEDEZE-R's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 25.7x | ||
KLINIQ Klinique Medical Clinic | 23.6x | 18.5% | ฿7.0b |
SAFE Safe Fertility Group | 18.7x | 13.2% | ฿4.3b |
GFC Genesis Fertility Center | 18.5x | 14.8% | ฿1.7b |
BKGI Bangkok Genomics Innovation | 42.1x | 26.2% | ฿1.6b |
MEDEZE-R Medeze Group | 39.5x | 25.0% | ฿10.7b |
Price-To-Earnings vs Peers: MEDEZE-R is expensive based on its Price-To-Earnings Ratio (39.5x) compared to the peer average (25.7x).
Price to Earnings Ratio vs Industry
How does MEDEZE-R's PE Ratio compare vs other companies in the TH Healthcare Industry?
Price-To-Earnings vs Industry: MEDEZE-R is expensive based on its Price-To-Earnings Ratio (39.5x) compared to the TH Healthcare industry average (23x).
Price to Earnings Ratio vs Fair Ratio
What is MEDEZE-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 39.5x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MEDEZE-R's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.